Treatment Options in Patients Suffering from Hemolytic-Uremic Syndrome: The Serbian Military Medical Academy Experience

Pubblicato online: 20 set 2022

Pagine: 237 - 242

Ricevuto: 27 giu 2019

Accettato: 16 set 2019

DOI: https://doi.org/10.2478/sjecr-2019-0060

Parole chiave

Hemolytic-uremic syndrome, atypical hemolytic-uremic syndrome, C3, corticosteroids, plasmapheresi

© 2022 Jelena Tadic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.